Loading patent…
AssigneeAlbert-Ludwigs-Universität Freiburg Körperschaft des öffentlichen Rechts
InventorsEvelyn ULLRICH, Tobias BEXTE, Philipp WENDEL, Robert ZEISER, Jan HABERMANN
Estimating the term…
The present invention relates to recombinant CAR-NK cells or CAR T-cells, expressing a CAR binding to the antigen CLEC12A or a functional alternatively spliced transcript variant thereof, wherein at least one immune checkpoint receptor protein, such as, for example NKG2A, CLEC12A, PD-1, TIM-3, TIGIT and/or KIRS, is inactivated. These highly functional immune check-point-inactivated CAR-NK cells or CAR T-cells target cancer-associated antigens or are adapted for a treatment of autoimmune diseases. Furthermore, the present invention relates to a non-virus-based method for producing a CAR-NK cell or CAR T-cell expressing an antigen-targeting chimeric antigen receptor (CAR) and a recombinant CAR-NK cell or CAR T-cell as produced, in particular a CAR-NK cell or CAR T-cell targeting the cancer-associated antigen CLEC12A. The present invention also relates to medical uses of the CAR-NK cell or CAR T-cell. The present invention further relates to a CAR-construct, comprising a modified CD8α or CD28
A recombinant CAR-NK cell or CAR T-cell, expressing a CAR binding to antigen CLEC12A or a functional alternatively-spliced transcript variant thereof, wherein at least one immune checkpoint receptor protein.
A CAR-construct, comprising a modified CD8α transmembrane domain comprising from 3 to 5 additional amino acids at the N-terminus and from 1 to 3 additional amino acids at the C-terminus of the CD8α or CD28 transmembrane (TM) domain.
A method for producing a CAR-NK cell or CAR-T-cell expressing an antigen-targeting chimeric antigen receptor (CAR) or a functional alternatively-spliced transcript variant thereof, comprising the steps of:
Dependencies are inferred from the claim text.